Anesthetic effects of a mixture of xylazine, ketamine, and buprenorphine in laboratory rats subjected to short surgical procedures

在接受短时外科手术的实验大鼠中,使用赛拉嗪、氯胺酮和丁丙诺啡混合物进行麻醉的效果

阅读:1

Abstract

BACKGROUND: Rodents are commonly used as models in experimental procedures, and researchers often need to perform rapid manipulations involving sedation and analgesia. AIM: The aim of this study was to evaluate the validity of the combination of xylazine and ketamine in association with buprenorphine in experimental rats undergoing short-term surgical procedures. METHODS: Twenty-six male rats were enrolled in experiments. Thirty minutes before the start of the procedure, buprenorphine (0.05 mg/Kg) was administered subcutaneously. The sedative protocol included intraperitoneal (IP) administration of 70 mg/Kg ketamine and 10 mg/Kg xylazine. Additionally, at the end of the procedure, all rats received 0.1 mg/Kg of atipamezole IP. Immediately before sedation and at 5, 10, 15, and 20 minutes after atipamezole administration, the main cardiorespiratory parameters were recorded. In addition, induction time, depth of anesthesia, duration of the procedure, recovery time, and pain score were recorded. RESULTS: The mean induction time was 2.29 ± 0.95 minutes. At the time of surgery, all subjects showed a deep anesthetic plane (score ≥ 3), and no response to skin incision was observed (score = 0). The time to recovery from the righting reflex after atipamezole administration was 3.66 ± 1.09 minutes. No rats showed signs of pain based on the rat Grimace scale. CONCLUSION: Our results suggested that the association of opioids with the xylazine/ketamine protocol ensures rapid induction and good analgesia during short procedures with mild/moderate painful stimulation. Furthermore, the administration of atipamezole facilitates rapid recovery and resumption of motor activity.

特别声明

1、本页面内容包含部分的内容是基于公开信息的合理引用;引用内容仅为补充信息,不代表本站立场。

2、若认为本页面引用内容涉及侵权,请及时与本站联系,我们将第一时间处理。

3、其他媒体/个人如需使用本页面原创内容,需注明“来源:[生知库]”并获得授权;使用引用内容的,需自行联系原作者获得许可。

4、投稿及合作请联系:info@biocloudy.com。